These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32667998)

  • 21. Resistance to Dolutegravir-A Chink in the Armor?
    Kuritzkes DR
    J Infect Dis; 2018 Jul; 218(5):673-675. PubMed ID: 29617815
    [No Abstract]   [Full Text] [Related]  

  • 22. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptotic colitis owing to dolutegravir.
    Martín-Vicente N; Rodríguez-Lago I; Barredo Santamaría I; Cabriada JL
    Gastroenterol Hepatol; 2020 Dec; 43(10):638-639. PubMed ID: 32680730
    [No Abstract]   [Full Text] [Related]  

  • 24. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
    Taiwo BO; Quiñones-Mateu ME; Smith K; Zheng L; Gulick R; Nyaku AN; Sax PE; Ha B; Kumwenda J; Olefsky M; Godfrey C; Wallis C
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):254-255. PubMed ID: 31914799
    [No Abstract]   [Full Text] [Related]  

  • 25. Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
    Giacomelli A; Conti F; Rusconi S
    EBioMedicine; 2020 Jun; 56():102820. PubMed ID: 32512519
    [No Abstract]   [Full Text] [Related]  

  • 26. Lessons from dolutegravir and neural tube defects.
    Abrams E; Myer L
    Lancet HIV; 2021 Jan; 8(1):e3-e4. PubMed ID: 33387476
    [No Abstract]   [Full Text] [Related]  

  • 27. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
    Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
    Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
    Bollen P; Freriksen J; Konopnicki D; Weizsäcker K; Hidalgo Tenorio C; Moltó J; Taylor G; Alba-Alejandre I; van Crevel R; Colbers A; Burger D;
    Clin Infect Dis; 2021 Jan; 72(1):121-127. PubMed ID: 32103260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacement.
    Bollen PDJ; Prins HAB; Colbers A; Velthoven-Graafland K; Rijnders BJA; de Vries-Sluijs TEMS; van Nood E; Nouwen J; Bax H; de Mendonca Melo M; Verbon A; Burger DM; Rokx C
    J Antimicrob Chemother; 2021 Apr; 76(5):1273-1276. PubMed ID: 33544819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine".
    Walimbwa S; Lamorde M; Waitt C; Amara A; Khoo S
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 31126921
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter to the editor re: Cabrera et al., 2019 'The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid'.
    Romach EH; Stanislaus D; Zamek-Gliszczynski MJ
    AIDS; 2020 Jan; 34(1):162-163. PubMed ID: 31789892
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter to the editor in re: Mohan et al., 2020 'dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels'.
    Romach EH; Posobiec LM; Bloomer JC; Zamek-Gliszczynski MJ; Stanislaus DJ
    EBioMedicine; 2021 Apr; 66():103335. PubMed ID: 33857900
    [No Abstract]   [Full Text] [Related]  

  • 33. What will it take to refute the possible safety signal for dolutegravir and neural tube defects?
    Zash RM
    BJOG; 2019 Oct; 126(11):1346. PubMed ID: 31283097
    [No Abstract]   [Full Text] [Related]  

  • 34. No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir.
    Ciccullo A; Dusina A; Lassandro AP; Borghetti A; Baldin G; Di Giambenedetto S
    AIDS; 2020 May; 34(6):956-957. PubMed ID: 32271256
    [No Abstract]   [Full Text] [Related]  

  • 35. An eco- friendly, selective, and sensitive spectrofluorimetric method for the quantification of Dolutegravir in its bulk and tablet dosage form.
    Alossaimi MA; El Gamal RM; Altharawi A; Abbas M
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 May; 273():121035. PubMed ID: 35193000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
    N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.
    Shin SS; Modongo C; Zetola NM
    Clin Infect Dis; 2020 Jun; 71(1):242-243. PubMed ID: 32436563
    [No Abstract]   [Full Text] [Related]  

  • 39. Preparation of the Key Dolutegravir Intermediate via MgBr
    Kong J; Xia H; He R; Chen H; Yu Y
    Molecules; 2021 May; 26(10):. PubMed ID: 34064812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
    Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.